CLDN18 and gastric cancer: Moreover, a phase III trial combining chemotherapy (CAPOX or mFOLFOX6) and pembrolizumab with or without zolbetuximab as first-line therapy in advanced or metastatic GC/GEJC whose tumors are HER2-negative, CLDN18.2-positive, and PD-L1-positive is underway (NCT06901531).